A Phase I, Randomized, Safety and Pharmacokinetics Study of AZD3152 in Healthy Adults (Little DIPPER)
Latest Information Update: 06 Sep 2024
At a glance
- Drugs Sipavibart (Primary) ; Sipavibart (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Pharmacokinetics
- Acronyms Little DIPPER
- Sponsors AstraZeneca
- 04 Sep 2024 Status changed from active, no longer recruiting to completed.
- 21 May 2024 Planned End Date changed from 9 Aug 2024 to 16 Aug 2024.
- 21 May 2024 Planned primary completion date changed from 9 Aug 2024 to 16 Aug 2024.